Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free AXSM Stock Alerts

Axsome Therapeutics (AXSM) Competitors

Axsome Therapeutics logo
$221.64 -8.36 (-3.63%)
Closing price 07/20/2026 04:00 PM Eastern
Extended Trading
$226.08 +4.44 (+2.00%)
As of 07/20/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AXSM vs. JAZZ, RVMD, TEVA, ONC, and MRNA

Should you buy Axsome Therapeutics stock or one of its competitors? MarketBeat compares Axsome Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Axsome Therapeutics include Jazz Pharmaceuticals (JAZZ), Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), and Moderna (MRNA). These companies are all part of the "medical" sector.

How does Axsome Therapeutics compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Jazz Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Axsome Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$4.27B3.58-$356.15M-$0.02N/A
Axsome Therapeutics$638.50M17.86-$183.17M-$3.73N/A

In the previous week, Axsome Therapeutics had 4 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 14 mentions for Axsome Therapeutics and 10 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.94 beat Axsome Therapeutics' score of 0.61 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jazz Pharmaceuticals
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Axsome Therapeutics
3 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Jazz Pharmaceuticals has a net margin of 0.66% compared to Axsome Therapeutics' net margin of -26.59%. Jazz Pharmaceuticals' return on equity of 14.56% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals0.66% 14.56% 5.25%
Axsome Therapeutics -26.59%-267.16%-28.53%

Jazz Pharmaceuticals presently has a consensus price target of $259.06, suggesting a potential upside of 6.40%. Axsome Therapeutics has a consensus price target of $261.48, suggesting a potential upside of 17.97%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
2.90
Axsome Therapeutics
1 Sell rating(s)
0 Hold rating(s)
20 Buy rating(s)
1 Strong Buy rating(s)
2.95

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Axsome Therapeutics beats Jazz Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Axsome Therapeutics compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Revolution Medicines presently has a consensus target price of $144.06, indicating a potential downside of 20.14%. Axsome Therapeutics has a consensus target price of $261.48, indicating a potential upside of 17.97%. Given Axsome Therapeutics' higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Revolution Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revolution Medicines
1 Sell rating(s)
1 Hold rating(s)
18 Buy rating(s)
2 Strong Buy rating(s)
2.95
Axsome Therapeutics
1 Sell rating(s)
0 Hold rating(s)
20 Buy rating(s)
1 Strong Buy rating(s)
2.95

Axsome Therapeutics has higher revenue and earnings than Revolution Medicines. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$11.58M3,311.82-$1.13B-$7.07N/A
Axsome Therapeutics$638.50M17.86-$183.17M-$3.73N/A

Revolution Medicines has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 8 more articles in the media than Revolution Medicines. MarketBeat recorded 14 mentions for Axsome Therapeutics and 6 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.54 beat Axsome Therapeutics' score of 0.61 indicating that Revolution Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revolution Medicines
5 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Axsome Therapeutics
3 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Revolution Medicines has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Revolution Medicines' return on equity of -83.22% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Revolution MedicinesN/A -83.22% -59.06%
Axsome Therapeutics -26.59%-267.16%-28.53%

Summary

Revolution Medicines and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Axsome Therapeutics compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Axsome Therapeutics' net margin of -26.59%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries9.01% 43.53% 8.19%
Axsome Therapeutics -26.59%-267.16%-28.53%

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.06$1.41B$1.3323.28
Axsome Therapeutics$638.50M17.86-$183.17M-$3.73N/A

Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

Teva Pharmaceutical Industries currently has a consensus price target of $41.78, indicating a potential upside of 34.92%. Axsome Therapeutics has a consensus price target of $261.48, indicating a potential upside of 17.97%. Given Teva Pharmaceutical Industries' higher possible upside, research analysts clearly believe Teva Pharmaceutical Industries is more favorable than Axsome Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80
Axsome Therapeutics
1 Sell rating(s)
0 Hold rating(s)
20 Buy rating(s)
1 Strong Buy rating(s)
2.95

In the previous week, Axsome Therapeutics had 2 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 14 mentions for Axsome Therapeutics and 12 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.48 beat Axsome Therapeutics' score of 0.61 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
11 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Axsome Therapeutics
3 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Teva Pharmaceutical Industries beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Axsome Therapeutics compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

BeOne Medicines has a net margin of 8.94% compared to Axsome Therapeutics' net margin of -26.59%. BeOne Medicines' return on equity of 12.06% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BeOne Medicines8.94% 12.06% 6.69%
Axsome Therapeutics -26.59%-267.16%-28.53%

BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

BeOne Medicines presently has a consensus target price of $390.92, indicating a potential upside of 25.87%. Axsome Therapeutics has a consensus target price of $261.48, indicating a potential upside of 17.97%. Given BeOne Medicines' higher probable upside, equities analysts plainly believe BeOne Medicines is more favorable than Axsome Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BeOne Medicines
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.80
Axsome Therapeutics
1 Sell rating(s)
0 Hold rating(s)
20 Buy rating(s)
1 Strong Buy rating(s)
2.95

BeOne Medicines has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BeOne Medicines$5.34B6.38$286.93M$4.4769.48
Axsome Therapeutics$638.50M17.86-$183.17M-$3.73N/A

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BeOne Medicines and BeOne Medicines both had 14 articles in the media. Axsome Therapeutics' average media sentiment score of 0.61 beat BeOne Medicines' score of 0.42 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BeOne Medicines
6 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Axsome Therapeutics
3 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

BeOne Medicines beats Axsome Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Axsome Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Axsome Therapeutics has lower revenue, but higher earnings than Moderna. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$1.94B12.14-$2.82B-$8.15N/A
Axsome Therapeutics$638.50M17.86-$183.17M-$3.73N/A

Moderna has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 3 more articles in the media than Moderna. MarketBeat recorded 14 mentions for Axsome Therapeutics and 11 mentions for Moderna. Axsome Therapeutics' average media sentiment score of 0.61 beat Moderna's score of 0.18 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Moderna
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Neutral
Axsome Therapeutics
3 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

75.3% of Moderna shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Axsome Therapeutics has a net margin of -26.59% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Moderna-143.55% -26.64% -19.32%
Axsome Therapeutics -26.59%-267.16%-28.53%

Moderna presently has a consensus target price of $38.80, indicating a potential downside of 34.78%. Axsome Therapeutics has a consensus target price of $261.48, indicating a potential upside of 17.97%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moderna
5 Sell rating(s)
10 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
1.82
Axsome Therapeutics
1 Sell rating(s)
0 Hold rating(s)
20 Buy rating(s)
1 Strong Buy rating(s)
2.95

Summary

Axsome Therapeutics beats Moderna on 12 of the 17 factors compared between the two stocks.

Get Axsome Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AXSM vs. The Competition

Export
MetricAxsome TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$11.84B$3.69B$6.89B$12.28B
Dividend YieldN/A2.16%2.67%9.39%
P/E Ratio-59.4220.4927.0623.94
Price / Sales17.86300.39517.5191.94
Price / CashN/A60.3126.6847.25
Price / Book126.657.9210.666.14
Net Income-$183.17M$23.81M$3.60B$331.74M
7 Day Performance-5.79%-1.09%-1.23%-1.81%
1 Month Performance-11.52%2.56%1.10%-1.44%
1 Year Performance102.08%42.16%23.65%16.33%

Axsome Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AXSM
Axsome Therapeutics
3.9579 of 5 stars		$221.64
-3.6%		$261.48
+18.0%		+98.4%$11.84B$638.50MN/A380
JAZZ
Jazz Pharmaceuticals
3.764 of 5 stars		$236.97
-2.8%		$252.88
+6.7%		+115.7%$15.32B$4.27BN/A2,890
RVMD
Revolution Medicines
1.9416 of 5 stars		$183.95
-1.6%		$144.00
-21.7%		+371.0%$39.73B$11.58MN/A250
TEVA
Teva Pharmaceutical Industries
4.7998 of 5 stars		$32.15
-2.4%		$41.78
+29.9%		+92.6%$37.89B$17.26B24.1733,950
ONC
BeOne Medicines
4.6781 of 5 stars		$303.96
+1.8%		$391.38
+28.8%		+5.4%$32.77B$5.34B68.0012,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AXSM) was last updated on 7/21/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel